Archives for 

Neulasta

Breaking News: CAFC Affirms in Amgen v. Apotex

Amgen v. Apotex (pegfilgrastim)  •  Biosimilar News  •  Patent Dance  •  U.S. Biosimilar Litigation News  •  U.S. District Court Decisions
The Federal Circuit issued its decision in Amgen v. Apotex (re: Apotex’s Neulasta biosimilar) this morning.  The Court affirmed the district court, holding that the commercial-marketing provision in 42 U.S.C. § 262(l)(8)(A) is mandatory and enforceable […]

View More